Clovis Oncology (NASDAQ:CLVS)

zzlangerhans (99.77) Submitted: 12/3/2012 5:55:04 PM : Start Price: $15.66 CLVS Score: -109.61

400M isn't an outrageous market cap for a company with 163M in cash and two early stage oncology candidates. The thing is, Clovis had the same valuation in August when topline results of their pivotal trial of their lead oncology candidate were still pending. Even though the share price ran up ahead of the crash when the trial failed and development of the lead candidate was terminated, it doesn't make sense for the stock to be running up again so quickly. I think the street is still showing overconfidence in this management team.